Human Umbilical Cord Mesenchymal Stem Cells-Derived Extracellular Vesicles for Rat Jawbone Regeneration in Periapical Periodontitis
Source abstract
Abstract
Extracellular vesicles derived from mesenchymal stem cells (MSCs-EVs) have great potential for bone remodeling and anti-inflammatory therapy. For the repair and reconstruction of inflammatory jawbone defects caused by periapical periodontitis, bone meal filling after debridement is commonly used in the clinic. However, this treatment has disadvantages such as large individual differences and the need for surgical operation. Therefore, it is of great significance to search for other bioactive substances that can promote jawbone regeneration in periapical periodontitis. Herein, it is found that CT results showed that local injection of human umbilical cord mesenchymal stem cells-derived extracellular vesicles (HUC-MSCs-EVs) and bone meal filling into the alveolar bone defect area could promote bone tissue regeneration using a rat model of a jawbone defect in periapical periodontitis. Histologically, the new periodontal tissue in the bone defect area was thicker, and the number of blood vessels was higher by local injection of HUC-MSCs-EVs, and fewer inflammatory cells and osteoclasts were formed compared to bone meal filling. In vitro, HUC-MSCs-EVs can be internalized by rat bone marrow mesenchymal stem cells (BMSCs), enhancing the ability for proliferation and migration of BMSCs. Additionally, 20 μg/mL HUC-MSCs-EVs can facilitate the expression of osteogenic genes and proteins including runt-related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), and osteopontin (OPN). In summary, in vivo and in vitro experiments showed that HUC-MSCs-EVs can promote bone regeneration in periapical periodontitis, and the effect of tissue regeneration is better than that of traditional bone meal treatment. Therefore, local injection of HUC-MSCs-EVs may be an effective method to promote jawbone regeneration in periapical periodontitis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Mesenchymal stem cell research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei 230001, China
Department of Stomatology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Funding
Fundamental Research Funds for the Central Universities
References (54)
Show source-provided references
1. 10.1111/j.1600-0757.1997.tb00098.x10.1111/j.1600-0757.1997.tb00098.x ↗
2. 10.1016/j.tripleo.2010.08.00710.1016/j.tripleo.2010.08.007 ↗
3. 10.1080/21655979.2021.193220910.1080/21655979.2021.1932209 ↗
4. 10.1186/s13287-021-02407-510.1186/s13287-021-02407-5 ↗
5. 10.1038/s41467-023-39958-510.1038/s41467-023-39958-5 ↗
6. 10.1021/acsami.0c0660910.1021/acsami.0c06609 ↗
7. 10.1186/s13287-021-02468-610.1186/s13287-021-02468-6 ↗
8. 10.7150/thno.7494210.7150/thno.74942 ↗
9. 10.1177/096368972097539110.1177/0963689720975391 ↗
10. 10.1186/s13287-022-02832-010.1186/s13287-022-02832-0 ↗
11. 10.1016/j.cell.2019.02.02910.1016/j.cell.2019.02.029 ↗
12. 10.1080/20013078.2018.153575010.1080/20013078.2018.1535750 ↗
13. 10.1002/INMD.2022000710.1002/INMD.20220007 ↗
14. 10.1111/cpr.1257010.1111/cpr.12570 ↗
15. 10.1186/s12951-021-01236-110.1186/s12951-021-01236-1 ↗
16. 10.1021/acsami.0c2267110.1021/acsami.0c22671 ↗
17. 10.1111/clr.1340110.1111/clr.13401 ↗
18. 10.1186/s13287-020-1562-910.1186/s13287-020-1562-9 ↗
19. 10.1016/j.jconrel.2023.01.07110.1016/j.jconrel.2023.01.071 ↗
20. 10.1177/0022034522113371610.1177/00220345221133716 ↗
21. 10.1016/j.actbio.2020.12.04610.1016/j.actbio.2020.12.046 ↗
22. 10.1186/s13287-022-02767-610.1186/s13287-022-02767-6 ↗
23. 10.2147/IJN.S40966410.2147/IJN.S409664 ↗
24. 10.1186/s13287-022-02764-910.1186/s13287-022-02764-9 ↗
25. 10.1002/INMD.2023001110.1002/INMD.20230011 ↗
26. 10.1002/adfm.20221166410.1002/adfm.202211664 ↗
27. 10.1002/ctm2.164610.1002/ctm2.1646 ↗
28. 10.1002/INMD.2022001810.1002/INMD.20220018 ↗
29. 10.1021/acsbiomaterials.9b0136310.1021/acsbiomaterials.9b01363 ↗
30. 10.1021/acsnano.1c0715010.1021/acsnano.1c07150 ↗
31. 10.1021/acsnano.3c1154210.1021/acsnano.3c11542 ↗
32. 10.1002/0471143030.cb0322s3010.1002/0471143030.cb0322s30 ↗
33. 10.1080/20013078.2019.169702810.1080/20013078.2019.1697028 ↗
34. 10.1016/j.jconrel.2022.12.05310.1016/j.jconrel.2022.12.053 ↗
35. 10.1021/acsnano.2c1035110.1021/acsnano.2c10351 ↗
36. 10.1021/acsnano.1c0317710.1021/acsnano.1c03177 ↗
37. 10.1038/srep4562210.1038/srep45622 ↗
38. 10.1016/j.bioactmat.2023.05.00310.1016/j.bioactmat.2023.05.003 ↗
39. 10.1021/acsnano.0c0771410.1021/acsnano.0c07714 ↗
40. 10.1021/acs.nanolett.0c0092910.1021/acs.nanolett.0c00929 ↗
41. 10.1186/s12951-021-00958-610.1186/s12951-021-00958-6 ↗
42. 10.1016/j.actbio.2021.07.02610.1016/j.actbio.2021.07.026 ↗
43. 10.1021/acsami.7b1762010.1021/acsami.7b17620 ↗
44. 10.1021/acsnano.3c0442310.1021/acsnano.3c04423 ↗
45. 10.1161/STROKEAHA.121.03582110.1161/STROKEAHA.121.035821 ↗
46. 10.1002/adma.20210626510.1002/adma.202106265 ↗
47. 10.2147/IJN.S33606210.2147/IJN.S336062 ↗
48. 10.1016/j.actbio.2021.12.03510.1016/j.actbio.2021.12.035 ↗
49. 10.1016/j.xcrm.2022.10088110.1016/j.xcrm.2022.100881 ↗
50. 10.1016/j.actbio.2022.02.02610.1016/j.actbio.2022.02.026 ↗
51. 10.1186/s13287-020-01756-x10.1186/s13287-020-01756-x ↗
52. 10.1111/jre.1291210.1111/jre.12912 ↗
53. 10.1111/jre.1296910.1111/jre.12969 ↗
54. 10.1111/jre.1297410.1111/jre.12974 ↗